Sign up to SCR Digest, our FREE weekly newsletter, and receive our Notes emailed directly to you. Click here.

PBIO: Enters Biopharmaceutical Quality Control Market

By Grant Zeng, CFA


On December 20, 2017, PBIO (OTC:PBIO)announced the release of extensively redesigned software for its Barocycler 2320EXTREME instrument. 

This enhanced software was through the collaboration between PBIO and its biopharmaceutical company customers. Therefore, the release of the enhanced software marks PBIO’s entry into the biopharmaceutical market. 

The enhanced software makes the 2320EXT one of the few Good Manufacturing Practices (GMP) compliant, computer-controlled, sample preparation systems available in the worldwide life sciences market today. Having GMP-compliant features should allow the Barocycler 2320EXT to be used in multiple departments within the same company, and for multiple applications well beyond extraction and protein digestion, where the instrument is primarily used today.

The 2320EXT is primarily used in the sample preparation (tissues, cells, proteins, etc.) for analysis. Sample preparation market is estimated currently at $6 billion worldwide.

The newly released software specifically optimizes the Barocycler 2320EXT, together with associated consumables, for the rapid and reproducible quality control of biotherapeutics, such as monoclonal antibodies and antibody-drug conjugates (ADCs). The new software can track each process parameter in a secure format with a date and time stamp. It enables secure data storage, user management, and audit trails needed to comply with requirements of GMP in the biopharmaceutical manufacturing environment. 

It’s our belief that the new GMP compliant software will significantly expand the utility of the Barocycler 2320EXT within the biopharmaceutical market and will accelerate PBIO’s revenue growth in the coming years. 

PBIO Acquires All Assets of BaroFold, Inc.

On December 13, 2017, PBIO announced the acquisition of all assets of BaroFold, Inc., including all patents, equipment, and intellectual property relating to BaroFold's PreEMT™ high-pressure protein refolding technology.

PreEMT is a patented technology that employs high pressure for the disaggregation and controlled refolding of recombinant proteins into their native structures for desired pharmacological activity. The PreEMT technology platform is transformative and practical for biopharmaceutical manufacturing processes, offering substantially reduced production costs due to its increased process yield and throughput at high protein concentrations. The PreEMT technology is easily scalable and has been utilized for the cGMP production of Phase I through Phase III clinical materials.

PreEMT technology is complimentary to PBIO’s game-changing Pressure Cycling Technology (PCT). 

This acquisition significantly increases PBIO's IP estate in high-pressure technologies with the addition of eight issued and several pending patents. These patents give PBIO freedom to operate in several important areas for biologics research and manufacturing: protein folding, re-folding and disaggregation. They also provide PBIO the right to grant licenses to third parties to practice the PreEMT and other technologies in both research laboratories and in biopharmaceutical manufacturing, the latter being a very large and rapidly growing field.

SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. 

DISCLOSURE: Zacks SCR has received compensation from the issuer directly or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks provides and Zacks receives quarterly payments totaling a maximum fee of $30,000 annually for these services. Full Disclaimer HERE.
User ID:
Remember my ID: